中国药物警戒
中國藥物警戒
중국약물경계
CHINESE JOURNAL OF PHARMACOVIGILANCE
2014年
5期
291-294
,共4页
郑冬雁%翟淑越%崔冉%路长飞
鄭鼕雁%翟淑越%崔冉%路長飛
정동안%적숙월%최염%로장비
抗肿瘤药物%不良反应%骨髓抑制
抗腫瘤藥物%不良反應%骨髓抑製
항종류약물%불량반응%골수억제
antitumor drugs%adverse reaction%bone marrow suppression
目的:了解抗肿瘤药品不良反应发生的特点和规律,探讨骨髓抑制发生的特点及影响因素,为临床合理应用抗肿瘤药物,预防或减少不良反应的产生提供参考依据。方法对2012年度我省4120例抗肿瘤药品不良反应报告进行回顾性分析。结果4120例抗肿瘤药物的不良反应报告中,铂类、植物来源抗肿瘤药物及其衍生物、其他抗肿瘤药及辅助治疗药物报告数较多。消化系统是发生不良反应累及最多的系统,其次是血液系统、皮肤及其附件。血液系统损害以骨髓抑制为主,骨髓抑制报告数最多的药品是顺铂,其次是多西他赛、吉西他滨、紫杉醇等。结论应加强抗肿瘤药品不良反应监测,重视骨髓抑制产生的危害,促进合理用药,预防或减少不良反应的发生。
目的:瞭解抗腫瘤藥品不良反應髮生的特點和規律,探討骨髓抑製髮生的特點及影響因素,為臨床閤理應用抗腫瘤藥物,預防或減少不良反應的產生提供參攷依據。方法對2012年度我省4120例抗腫瘤藥品不良反應報告進行迴顧性分析。結果4120例抗腫瘤藥物的不良反應報告中,鉑類、植物來源抗腫瘤藥物及其衍生物、其他抗腫瘤藥及輔助治療藥物報告數較多。消化繫統是髮生不良反應纍及最多的繫統,其次是血液繫統、皮膚及其附件。血液繫統損害以骨髓抑製為主,骨髓抑製報告數最多的藥品是順鉑,其次是多西他賽、吉西他濱、紫杉醇等。結論應加彊抗腫瘤藥品不良反應鑑測,重視骨髓抑製產生的危害,促進閤理用藥,預防或減少不良反應的髮生。
목적:료해항종류약품불량반응발생적특점화규률,탐토골수억제발생적특점급영향인소,위림상합리응용항종류약물,예방혹감소불량반응적산생제공삼고의거。방법대2012년도아성4120례항종류약품불량반응보고진행회고성분석。결과4120례항종류약물적불량반응보고중,박류、식물래원항종류약물급기연생물、기타항종류약급보조치료약물보고수교다。소화계통시발생불량반응루급최다적계통,기차시혈액계통、피부급기부건。혈액계통손해이골수억제위주,골수억제보고수최다적약품시순박,기차시다서타새、길서타빈、자삼순등。결론응가강항종류약품불량반응감측,중시골수억제산생적위해,촉진합리용약,예방혹감소불량반응적발생。
Objective To study regularities and characteristics of adverse drug reaction(ADR) induced by the antitumor drugs, analyze characteristics and influence factors of the bone marrow depression induced by antitumor drugs, and provide references for the clinical rational use of antitumor drugs, so as to prevent or reduce the ADRs. Methods 4 120 reports of ADR induced by antitumor drugs in 2012 in our province were retrospectively analyzed. Results In the 4 120 ADR reports of antitumor drugs, the number of ADR report was higher in platinum, plant sources of antitumor drug and its derivatives, other antitumor drugs and adjuvant therapy drugs. The digestive system was the most adverse reactions involving system, followed by the blood system, skin and its accessory. Damage in the blood system was mainly caused by bone marrow suppression. In the bone marrow suppression induced by antitumor drugs, cisplatin resulted in the highest incidence of bone marrow suppression, followed by docetaxel, gemcitabine, paclitaxel, etc. Conclusion We should strengthen the monitoring of adverse events of antitumor drugs, pay more attention to the damage caused by bone marrow suppression, promote rational drug use, and prevent or reduce the incidence of ADRs.